Head-to-head evidence
HRS-1301 vs Inclisiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
HRS-1301
Developed by Jiangsu Hengrui Pharmaceuticals and partners
NCT06857253 · Phase 1 · completed
This is a real randomized, blinded, placebo-controlled study, which is a solid design, but its primary measure is adverse-event safety monitoring rather than a cholesterol or cardiovascular outcome, and results have not been posted yet.
Inclisiran · Leqvio
Marketed by Novartis and partners
NCT03397121 · Phase 3 · completed
The trial randomly assigned 482 participants to double-blind inclisiran or placebo, with 242 receiving inclisiran and 240 receiving placebo. Both primary LDL-C comparisons were statistically significant in favor of inclisiran, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical outcome, supporting a moderate evidence grade.
Next expected readout: October 2026 · NCT05360446 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-1301's landscape · Inclisiran's landscape